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Abstract Neuropathic pain and inflammatory pain are two
common types of pathological pain in human health
problems. To date, normal painkillers are only partially
effective in treating such pain, leading to a tremendous
demand to develop new chemical entities to combat pain
and inflammation. A promising pharmacological treatment
is to control signal transduction via the inflammatory
mediator-coupled receptor protein C5aR by finding antag-
onists to inhibit C5aR activation. Here, we report the first
computational study on the identification of non-peptide
natural compound inhibitors for C5aR by homology mod-
eling and virtual screening. Our study revealed a novel
natural compound inhibitor Acteoside with better docking
scores than all four existing non-peptidic natural com-
pounds. The MM-GBSA binding free energy calculations
confirmed that Acteoside has a decrease of *39 kcal/mol
in the free energy of binding compared to the strongest
binding reference compound. Main contributions to the
higher affinity of Acteoside to C5aR are the exceptionally
strong lipophilic interaction, enhanced electrostatics and
hydrogen bond interactions. Detailed analysis on the
physiochemical properties of Acteoside suggests further
directions in lead optimization. Taken together, our study
proposes that Acteoside is a potential lead molecule tar-
geting the C5aR allosteric site and provides helpful infor-
mation for further experimental studies.
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Introduction
Natural products derived from plants, fungi, bacteria, and
marine organisms, which have long been utilized in Wes-
tern and Eastern medicine, are widely investigated by
modern science as ideal candidates for drug therapy. These
natural products are usually secondary metabolites that can
be easily metabolized by the human body and are
promising alternatives to synthetic drugs (Butler, 2004).
They have been found to apply in a plethora of pharma-
ceutical applications, which includes the use in treating
inflammatory, parasitic, metabolic, oncological, and pain-
related conditions (Saklani and Kutty, 2008). This
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emerging trend in pharmaceutical research is fueled by the
advances in ancillary technologies including spectroscopic,
chromatographic, biosynthetic, and synthetic methods, as
well as the ease in obtaining these isolates by synthetic or
combinatorial chemistry and molecular modeling (Ley and
Baxendale, 2002).
The most common types of pathological pain include
inflammatory and neuropathic pain both of which represent
important health problems. While inflammatory pain is a
crucial and classic manifestation of the inflammatory pro-
cess, neuropathic pain can arise from any of multiple nerve
lesions or diseases, with symptoms including hyperalgesia
or allodynia (Kidd, 2001; Baron et al., 2010). Even pain-
killers, like opioids and nonsteroidal anti-inflammatory
drugs (NSAID) which are generally very efficient, are only
partially effective; even worse, studies revealed that pro-
longed exposure to these painkillers can cause adverse
effects (Devulder et al., 2009). Consequently, there is
tremendous demand for identifying or developing new
chemical entities to combat pain by exploiting alternative
biological mechanisms that will involve fewer side effects.
Based on recent results from several animal models for
neuropathic pain, the G protein-coupled receptor C5aR has
emerged as one of the potential pharmacological targets for
treating neuropathic pain (Moriconi et al., 2014). As it is
widely expressed in inflammatory cells, C5aR binds to
anaphylatoxin C5a generated during complement system
activation to result in an effective clearance of infectious
agents (Gerard and Gerard, 1991). However, under various
pathological conditions, overproduction of C5a can down
regulate immune response and at the same time over
activate other cell types. This can lead to uncontrolled
inflammation and trigger proinflammatory and immuno-
suppressive disorders (Guo and Ward, 2005). Therefore,
finding antagonists to inhibit C5aR signaling provides a
promising way for improving the treatment of chronic pain.
Despite significant efforts over the past decades, the
development of peptide as antagonist regulator for C5aR
has been hampered by several issues related to cost
effectiveness and low oral bioavailability, lack of potency,
low selectivity, and poor drug-like properties. The most
successful so far has been the PMX-53, a cyclic pep-
tidomimetic antagonist designed to mimic the C-terminal
portion of C5a (Finch et al., 1999). Though it has shown
encouraging results in preclinical studies, its development
remains limited by its short half-life and disapproving
bioavailability (Ricklin and Lambris, 2007).
Previous studies have indicated that a minor pocket
spanning between transmembrane (TM) 1, 2, 3, 6, and 7 is
a key motif for the intracellular activation process. A study
by Alessio Moriconi and coworkers successfully combined
the information on structural and functional features of
allosteric sites in homologous chemokine receptors, to
perform de novo design of a new class of allosteric small
molecular weighted inhibitors of C5aR (Hodes et al.,
2014).
As mentioned earlier, natural ligands have certain
advantages over synthetic ones in terms of minimal side
effects. To cope with the increasing demand for non-pep-
tidic antagonists with high specificity against C5aR, in this
work, we performed computational studies of C5aR and
attempted to identify non-peptidic natural compounds as
potent inhibitors. To this end, we generated the three-di-
mensional structure model of C5aR using comparative
homology modeling and subsequently screening a library
of approximately 1500 natural compounds toward the TM
regions at the allosteric site of C5aR.
Materials and methods
Homology modeling of the structure of C5aR
A comparative modeling approach was implemented for
modeling of C5aR protein of the GPCR family. The 350
amino acid long protein sequence of C5aR (Accession no:
P21730) was retrieved from UniProt database in FASTA
format. PDB structures sharing a high degree of homology
with C5aR protein were identified as templates (PDB IDs:
2LNL, 2LOT, 4EA3, and 3PBL) on the basis of parameters
such as lowest E values, highest score, and the most
aligned regions by position-specific iterated basic align-
ment search tool (PSI-BLAST) and global alignment with
the query sequence. These templates were used to generate
homology models of C5aR using the multiple template
modeling approach using MODELLER 9.14 (Sali and
Blundell, 1993). Furthermore, this model structure was
subjected to assess with the DOPE score (Shen and Sali,
2006) and Ramachandran plot (Ramachandran et al.,
1963). It is remarked that since C5aR is a transmembrane
protein, most validation tools such as Profile 3D and
QMEAN (Benkert et al., 2011), which are statistical
methods derived from soluble protein structures, are not
suitable for assessment.
Protein model preparation
Using the Preparation wizard of Schro¨dinger software, the
C5aR homology model was processed through the steps of
water removal, bond order assignment, and addition of
hydrogen atom. It was then energy minimized using default
constraints of 0.30 A˚ RMSD using the OPLS-2005 force
field.
Since C5aR contains helix-connecting loops which are
involved in the ligand binding site, the Prime module in
Schro¨dinger was invoked for loop refinement. Prime loop
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prediction is an ab initio method, and it generates structures
of the loop segment by reference to a backbone dihedral
library. The generated loop structures are clustered, scored,
side chain refined, and energy minimized; only the best
scored structure is returned. While there is no perfect loop
modeling method at the moment, a recent assessment of
loop prediction methods revealed that only Prime is able to
generate loop structure with \2.5 A˚ for loops up to 10
residues, while other methods (such as ICM, Sybyl, and
MODELLER) up to 7 residues (Rossi et al., 2007).
To assure the quality of the refined homology model,
MD simulation was conducted with the protein embedded
in POPC lipid bilayer and solvated in explicit water using
GROMOS 53A6 force field (Oostenbrink et al., 2004) for
protein and GROMOS 53A6L lipid force field for the
membrane (Poger and Mark, 2012). The protein RMSD
gave an average of *5.7 A˚ in 10 ns, indicating that there
were moderate fluctuations of the structure; we noted that
these fluctuations were focused in the intracellular region
(specifically, residue 243 to 266, root-mean-square fluctu-
ations (RMSF)[5 A˚) which was far away from the ligand
binding site. Our analysis also showed that binding site
residues had very low RMSF values of\2 A˚. These results
proved the validity of our homology model for undertaking
further docking studies.
Ligand library preparation
The ligand library was compiled from various databases
and from literature survey. A total of 1500 natural small
molecules were retrieved in SDF format from PubChem
database (Bolton et al., 2008) and ZINC (Irwin et al.,
2012). These small natural compounds were prepared using
the ligprep module of Schro¨dinger by assigning the bond
orders and angles. Furthermore, those molecules were
subjected to minimization using the OPLS-2005 force field.
Grid generation
The C5aR structure was subjected to SiteMap analysis
(Halgren, 2009) and yielded five active sites. Based on the
SiteScore values, site 1 was chosen to perform molecular
docking studies. The active sites predicted by SiteMap are
Gln 149, Ala 193, Asp 255, Leu 264, Ile 223, and Glu 191.
The grid box was generated around the minor pocket
spanning between TM-1, -2, -3, -6, and -7. This region was
set as the centroid using the Receptor grid generation tab
of the Glide module in Schro¨dinger.
QikProp analysis
The QikProp module (Qikpro 4.2 2014) of Schro¨dinger was
used for efficient evaluation of pharmaceutically relevant
properties of natural compounds library; it predicts the
Absorption, Distribution, Metabolism, Elimination
(ADME) properties of all natural compounds. The com-
pounds which were screened by Glide and their predicted
ADME properties are discussed in the next section.
Virtual screening
High throughput virtual screening was implemented by
Schro¨dinger software through the virtual screening work-
flow of Glide. Three steps were executed according to the
workflow, which includes HTVS, SP (standard-precision)
docking, and XP (extra precision) docking. Based on this
screening process, we have screened the 1500 natural
compound library against the C5aR structure. Compounds
which were screened successfully from HTVS were further
subjected to SP docking for higher precision docking to get
more accurate results. Furthermore, XP docking was car-
ried out to remove the false-positive results.
Binding free energy calculation
Next to docking, Prime Molecular Mechanics/Generalized-
Born/Surface Area (MM-GBSA) (Prime 2.1, 2009) (Ras-
telli et al., 2010) was used for the calculation of binding
free energy for the docked complexes. The method used
the following equation:
DGbind ¼ DEMM þ DGSOLV þ DGSA; ð1Þ
where DEMM is the difference in the minimized energies
between the C5aR–inhibitor complex and the total of
energies of unliganded C5aR and inhibitor; DGSOLV is the
difference in the GBSA solvation energy of the protein–
inhibitor complex and the total of the solvation energies for
the unliganded C5aR and inhibitor; DGSA is the change in
surface area energies for the complex and the totality of the
surface area energies for the unliganded C5aR and inhi-
bitor. All ligand poses were further minimized using the
local optimization by Prime where the energies of com-
plexes were calculated with the OPLS-2005 force field and
Generalized-Born/Surface area continuum solvent model.
While the simulation process, the ligand strain energy was
also taken into consideration.
Results and discussion
The C5aR homology model
Owing to unavailability of experimental structure of the
C5aR protein, homology modeling was employed to obtain
the tertiary structure. This was accomplished by taking
crystal structure of other GPCR proteins which shared a
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high degree of sequence similarity and lowest E values
with C5aR. Figure 1 shows the ClustalW2 multiple
sequence alignment result of the template PDBs—2LNL,
2LOT, 4EA3, and 3PBL, against the query sequence
C5AR1_HUMAN. All template proteins showed an iden-
tity of*40 % each and with a query coverage of[90 % in
the amino acid region 160–240 and 270–280. Multiple
sequence alignment shows a high degree of conservation of
the amino acid residues involved in non-peptide binding
site in all four templates used for modeling. Using the
MODELLER program, five models were generated taking
the multiple templates. The model with the lowest DOPE
score was subjected to further structural assessment. As
shown in Fig. 2, the Ramachandran plot of the C5aR model
calculated that 97.8 % of all amino acids resided in the
most favored and additionally allowed regions. These data
suggest that the C5aR homology model was of good
quality and did not suffer any serious steric clashes.
Library of natural compounds and ADME-based
filtering
A comprehensive search for all natural compounds with
either characterized anti-inflammatory property or those
compounds with proven efficacy against Neuropathic pain
was made by searching the electronic literature on the
PubChem and ZINC database. All studies published
between 1970 and June 2015 in English language was
included in the analysis. A total of 1500 compounds were
identified which fulfilled the aforementioned criterion.
The enlisted natural compounds were filtered based on
their ADME properties using QikProp. The compounds
prepared were subjected to the druglikeness filter. The
criteria of the filter were set as follows: molecular weight
within 160–480, number of heavy atoms within 20–70,
lipophilicity within 40–130, number of hydrogen bond
donors within 4–7, number of hydrogen bond acceptors
within 8–12. All the ligands constituting the library of
natural compounds conformed to the above-mentioned
criterion and were subjected to the docking analysis using
Glide.
Identification of binding site
In accordance with previously available report, C5aR
structure is known to consist of three binding sites (Bowie
et al., 1991) and choosing the right one as the target for the
antagonist is a non-trivial task. To identify the correct
binding site, SiteMap analysis was performed on the C5aR
structure after the protein preparation steps. In total, Site-
Map recognized five active sites. By considering the
SiteScore and previously reported literature available about
the C5aR binding sites (Halgren, 2007), SiteMap-1 was
chosen for further molecular docking studies (Fig. 3). The
predicted active site consists of residues T29, F182, P184,
D191, P270, S271, S272, F275, S272, F275, and L276,
where majority of them were previously reported in (Rana
and Sahoo, 2015).
Docking of reference compounds
To set a cutoff value for docking studies, we docked all
previously reported non-peptidic antagonist molecules
including NDT9520492 (Waters et al., 2005), CP_447
(Blagg et al., 2008), NDT9513727 (Sumichika et al.,
2002), and W_54011 (Ames et al., 2001) using the XP
docking method. The results showed that NDT9520492 has
the highest binding affinity toward C5aR with the XP
GScore of -8.291 kcal/mol while CP_447, NDT9513727,
and W_54011 have -7.281, -5.966, and -5.466 kcal/mol,
respectively. Hence, for screening better lead structure, a
cutoff GScore value of -6.00 kcal/mol was set as the fil-
tering criteria in virtual screening (Fig. 4).
Virtual screening of natural ligands
As shown in Table 1, results of virtual screening found two
potential natural molecules with better GScore than the
reference compounds. Remarkably, Acteoside (PubChem
ID 5281800) with XP GScore of -12.366 kcal/mol showed
highest binding energy than all four previously reported
C5aR inhibitors. The ligand interaction map was generated
to get insight into their interaction patterns. As shown in
Fig. 5, the docked pose analysis of Acteoside revealed that
it formed 7 hydrogen bonds with the binding site of C5aR,
interacting with the pocket residues Arg206, Ser327,
Tyr300, Leu319, Arg320, Cys188, and Thr324. There are
several new residues reported here together with the crucial
binding residue Arg206, which was found as interacting
residue in all four reference compound complexes. The
residue Arg206 is positioned near the cytoplasmic surface;
it is helpful in recognition of allosteric pocket; and several
cyclic peptide antagonists are known to interact with
Arg206 (Kaneko et al., 1995). It is evident that reference
compounds NDT9520492, CP_447, NDT9513727, and
W_54011 are also involved in hydrogen bonding and pi–pi
interaction with the key residues Arg206 and Arg330.
Prime MM-GBSA calculation
The top-ranked molecules were further subjected to Prime
MM-GBSA calculations. Molecular Mechanics/General-
ized-Born/Surface Area (MM/GBSA)-based relative bind-
ing free energy quantification has emerged as an effective
tool to understand mutational effect in large biomolecular
systems (Massova, 2000). As presented in Table 2, the two
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Fig. 1 ClustalW2 result
showing the sequence alignment
of the template proteins (PDB
IDs: 2LOT, 2LNL, 3PBL and
4EA3) with that of the human
C5aR sequence
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novel natural ligands Acteoside and Toxicarioside were
found to have the strongest binding free energy (dG_bind)
of -113.884 and -90.083 kcal/mol, respectively, whereas
reference compounds have weaker binding free energies in
the range of -43 to -75 kcal/mol. Main contributions to
the tight binding of Acteoside to C5aR are the exception-
ally strong lipophilic interaction (dG_bind_Lipo),
enhanced electrostatics (dG_bind_Coulomb) and hydrogen
bond interactions (dG_bind_Hbond). Toxicarioside does
have strong hydrophobic interaction with the receptor
protein, but it has largely reduced electrostatic interaction
making it a less tight-binding ligand.
Comparison of physiochemical properties
of Acteoside and reference compounds
Considering Acteoside as a more potent inhibitor, we
performed QikProp analysis on it and compare to the
results of reference compounds. QikProp is a quick and
ADME program to predict physiochemical descriptors and
pharmaceutically relevant properties of organic molecules.
For each descriptor, the range satisfying 95 % of known
drugs is also provided for comparison.
As shown in Table 3, Acteoside is a molecule with the
largest molecular weight and possesses the largest solvent
accessible surface area and more hydrophobic components
compared to reference compounds. It possesses excep-
tionally large number of hydrogen bond donors and
acceptors. Among the 6 predicted partition coefficients, 4
of them fall within the recommended ranges: water/gas
(QPlogPw), aqueous solubility (QPlogS), brain/blood
(QPlogBB), and skin permeability (QPlogKp), whereas
octanol/gas partition coefficient (QPlogPoct) is beyond the
recommended range and octanol/water partition coefficient
(QPlogPo/w) is below.
It is noted that although all ligands are classified as low
in human oral absorption (HOA) Acteoside has the highest
predicted aqueous solubility of -1.658 (QPlogS) compared
to those in the reference compounds (-8.761 to -6.458,
3/4 of them are out of the recommended range of known
drugs). As low solubility limits absorption and causes low
oral bioavailability, a high oral bioavailability drug
potentially reduces the amount of administered drug nec-
essary to achieve the desired pharmacological effect while
reducing the risk of side effects and toxicity. Based on
these prediction results, it is suggested that Acteoside may
Fig. 2 Ramachandran plot of the C5aR homology model. Color red
indicates low-energy regions, yellow allowed regions, pale yellow the
generously allowed regions, and white disallowed regions (Color
figure online)
Fig. 3 Image displays SiteMap-1 identified in the SiteMap analysis
using the C5aR structure. The rectangle indicates the location of the
generated grid box used in further molecular docking studies. The
different color meshes show regions that have hydrophobic residues
(yellow), hydrogen bond donors (blue), and hydrogen bond acceptors
(red) (Color figure online)
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be a more potent drug candidate regarding its efficacy than
reference compounds.
Nevertheless, the three partition values octanol/gas,
water/gas, and octanol/water together suggest that Acteo-
side has low lipophilicity which may lead to low gas-
trointestinal absorption by the way of passive diffusion. For
diseases of the brain, another important consideration of
drug candidate is its brain penetration property. Although
within the recommended range, the predicted brain/blood
partition coefficient (QPlogBB) of Acteoside is only
-2.125, the smallest among all ligands. Both undesirable
properties of Acteoside can be explained by the large
Fig. 4 Ligand interaction map of NDT982042, CP_447, W_54011,
and NDT9513727. The proposed interaction modes of all four
reference compounds have been shown in the stick format. Residues
involve in hydrogen bonding are represented as pink dotted lines,
whereas pi–pi stacking are shown in green color arrow lines (Color
figure online)
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number of hydrogen bond donors and acceptors in its
structure. While hydrogen bonds can only contribute about
-3 kcal/mol to the free energy of binding (see Table 2),
further optimization of the Acteoside structure may con-
sider eliminating selected hydrogen bond donors or
acceptors in order to enhance its lipophilicity and thus its
blood–brain barrier permeability for drug targeting neuro-
pathic pain diseases.
Conclusion
In recent times, there has been an increased demand for
identifying or developing new chemical entities to combat
neuropathic and inflammatory diseases by exploiting
alternative biological mechanisms that will involve fewer
side effects. As a critical first step to drug design for
neuropathic and inflammatory diseases, a computational
study of the human C5aR was performed with the goal to
identify lead compounds from natural products. Using an
in-house prepared library of 1500 natural compounds, and
by virtue of homology modeling and virtual screening, two
novel natural compounds with low binding free energies
than reference compounds were identified. Energy calcu-
lations from docking, MM-GBSA, and ADME analysis
with QikProp unambiguously reveal that Acteoside is a
more potent lead compound with stronger binding inter-
actions with C5aR than currently known compounds.
Indeed, looking back into the literatures, the anti-in-
flammatory role of Acteoside has been confirmed previ-
ously by many experimental groups (Lee et al., 2006; Seo
et al., 2013). The compound has been used in Ayurvedic
and Chinese medicine for many years as an anti-inflam-
matory agent and has a large range of pharmacological and
biochemical effects (He et al., 2011) including anti-tumor
(Inoue et al., 1998), anti-nephritic (Hayashi et al., 1994),
anti-hepatotoxic (Lee et al., 2004), and antiseptic (Lee
et al., 2005) activities. Acteoside was also found to inhibit
the high-mobility group box 1 (HMGB1) release in vitro
and decrease serum and lung HMGB1 levels in CLP-in-
duced sepsis in vivo (Lee et al., 2006), presumably related
to the binding of C5a to the C5L2 protein (Rui et al., 2012),
a closest homology with C5aR. While the experimental
Table 1 GScores and the energy components of the top-ranked natural compounds and the reference compounds
Ligand XP GScore Glide Evdw Glide Ecoul Glide Einternal XP HBond G5aR residues with hydrogen bond with
docked ligand
Acteoside -12.366 -35.926 -22.838 13.976 -5.283 Arg206, Ser327, Tyr300, Leu319, Arg320,
Cys188, Thr324
Toxicarioside -8.871 -48.593 -10.579 5.321 -1.92 Tyr300, Ala303
NDT9520492 -8.291 -45.214 -14.721 7.249 -1.86 Arg206
CP_447 -7.281 -39.141 -19.084 4.341 -2.52 Arg206, Arg320
NDT9513727 -5.966 -23.561 -9.279 5.178 -0.98 Arg206, Arg330
W_54011 -5.466 -31.145 -8.324 4.214 -1.74 Arg206, Arg330
All energy values are in kcal/mol. C5aR protein residues having hydrogen bonds with the docked ligands are also listed in the last column
Fig. 5 (Top) Ligand interaction map of the lead molecule Acteoside
and (bottom) its proposed binding mode in the active site. The ligand
(orange) and the interacting protein residues (green) are displayed in
stick format. For better clarity, interacting residues TYR300,
LEU319, the nonpolar hydrogens in the ligand and TM helix in the
residue ID range 278–319 are not shown (Color figure online)
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structure of neither C5aR nor C5L2 is available, result
from pairwise sequence alignment of the human C5aR and
C5L2 (result not shown) reveals that the major interacting
residues at the active site ARG206, TYR300, CYS188 are
conserved in them, suggesting that Acteoside may bind in
them with a similar binding mode. Nevertheless, this is still
to be verified by further computational study via careful
homology modeling and molecular docking.
As a conclusion, our computational study proposes
Acteoside to be a better lead compound than all known
inhibitors. This promises a new gateway for the further
development of Acteoside as a potential anti-inflammatory
agent targeting the C5aR allosteric site. Biological exper-
iments to validate this inhibitor are being planned as a
future work.
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